Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, made by competing manufacturers (AbbVie and Johnson & Johnson). Both drugs belong to the same mechanism class and target the same cytokine subunit, so the skyrizi vs tremfya crohn's comparison often comes down to trial data, administration options, and maintenance convenience. This guide walks through the key differences to help you discuss the decision with your GI.
Same Class, Two Molecules
Skyrizi (risankizumab) and Tremfya (guselkumab) both bind the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 drives Th17 inflammation central to Crohn's disease pathology. The risankizumab vs guselkumab comparison is essentially a within-class decision, so the structural mechanism is shared, but the molecules differ in affinity, half-life, and the clinical programs that support each. Skyrizi gained Crohn's approval in June 2022. Tremfya gained Crohn's approval in March 2025 based on GALAXI-2 and GALAXI-3.
Trial Evidence: ADVANCE, MOTIVATE, FORTIFY vs GALAXI
Skyrizi's Crohn's approval rests on ADVANCE and MOTIVATE (induction) and FORTIFY (maintenance). ADVANCE enrolled biologic-naive and biologic-experienced Crohn's patients, while MOTIVATE focused on biologic-experienced patients. Both showed significantly higher clinical remission and endoscopic response on Skyrizi vs placebo at week 12, with FORTIFY confirming durability through week 52. Tremfya's Crohn's approval rests on GALAXI-2 and GALAXI-3, two pivotal phase 3 trials that compared guselkumab with placebo and with ustekinumab (Stelara). Tremfya demonstrated statistical superiority over Stelara on endoscopic response at week 48 in pooled analyses, establishing its Crohn's efficacy credentials. The SEQUENCE vs GALAXI comparison is informative because SEQUENCE established Skyrizi's superiority over Stelara in Crohn's endoscopic remission, and GALAXI did the same for Tremfya using its own head-to-head design.
Efficacy Comparison
No head-to-head trial has directly compared Skyrizi with Tremfya in Crohn's. Indirect comparisons from network meta-analyses suggest similar clinical remission and endoscopic response rates between the two drugs. Both perform well in biologic-naive and biologic-experienced populations. For skyrizi vs tremfya effectiveness, current data does not establish a clear winner, and clinical decision-making often defaults to administration preference, insurance coverage, and GI familiarity with each drug.
Administration and Dosing
Skyrizi for Crohn's uses IV induction at weeks 0, 4, and 8 (600 mg per infusion), followed by subcutaneous maintenance of 360 mg every 8 weeks via a prefilled cartridge and on-body injector, per AbbVie's prescribing information. Tremfya for Crohn's offers a distinctive dual induction pathway. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) per the GALAXI and GRAVITI programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. For Crohn's patients who want to avoid infusion center visits entirely, Tremfya's SC-only induction option is a meaningful practical advantage.
Safety Profiles
Both drugs have favorable safety profiles consistent with IL-23 p19 class effects. Long-term data from each drug's psoriasis and psoriatic arthritis programs supports low rates of serious infection and malignancy. For skyrizi vs tremfya side effects, common adverse events on both drugs include upper respiratory infections, injection site reactions, and headache. Neither drug has a black-box warning for lymphoma or other class-level serious adverse events seen with anti-TNFs. TB and hepatitis B screening is recommended before starting either drug.
Injection Experience
For patients maintaining on SC therapy, the injection experience differs. Skyrizi's Crohn's maintenance (360 mg every 8 weeks) uses an on-body injector cartridge that delivers over several minutes. Tremfya's maintenance (100 mg every 8 weeks) uses a standard prefilled syringe or One-Press autoinjector. Some patients prefer the quick injection of Tremfya's device, while others find the on-body injector convenient because they can move around during delivery. Trial a device demo with your GI or pharmacy before committing if possible.
Cost and Access
Both Skyrizi and Tremfya are branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in Crohn's. Manufacturer copay assistance programs exist for commercially insured patients on both drugs, and patient assistance foundations may help underinsured patients. For patients whose plans cover only one of the two drugs, the coverage decision often drives the choice. Where both are covered, the dosing schedule and device preference usually matter more than headline price.
Choosing With Your GI
For a Crohn's patient deciding between Skyrizi and Tremfya, the two drugs are more similar than different. Tremfya tends to win on induction flexibility (SC or IV) and a newer head-to-head trial (GALAXI) establishing its place in the IL-23 p19 class. Skyrizi tends to win on the longer Crohn's track record and established real-world data. Ask your GI which drug they have the most experience with, how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.